Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maternal colostrum is the initial milk produced by mothers after delivery, characterized by high concentrations of immunologically active components such as secretory immunoglobulin A (sIgA), lactoferrin, cytokines, and growth factors. In a clinical trial led by the Federal University of Uberlândia, colostrum was investigated as an oropharyngeal immunotherapy for very low birth weight (VLBW) preterm infants. The therapy involves the administration of small amounts of colostrum to the oropharyngeal mucosa to stimulate the oropharyngeal-associated lymphoid tissue (OALT) and gut-associated lymphoid tissue (GALT), thereby enhancing the infant's immune defenses against late-onset sepsis. While the biological rationale is strong, the specific randomized, double-blind, placebo-controlled trial involving 113 infants did not demonstrate a statistically significant reduction in sepsis, possibly due to the high rate of early breast milk feeding in the control group.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maternal colostrum.